Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 2004 March;46(1) > Panminerva Medica 2004 March;46(1):61-74

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

PANMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

REVIEWS  


Panminerva Medica 2004 March;46(1):61-74

lingua: Inglese

Hematopoietic stem cell transplantation in hematologic malignancy

Archuleta T. D., Devetten M. P., Armitage J. O.

Section of Hematology/Oncology Department of Internal Medicine University of Nebraska Medical Center, Omaha, NE, USA


PDF  


Hematopoietic ­stem ­cell trans­plan­ta­tion has ­become increas­ing­ly impor­tant in the treat­ment of hemat­o­log­ic malig­nan­cies ­over the ­past 20 ­years. While it is asso­ciat­ed ­with sig­nif­i­cant mor­bid­ity, it ­offers the ­only ­chance of ­cure in ­many cir­cum­stanc­es. Autologous and allog­e­ne­ic trans­plan­ta­tion ­have ­been ­used suc­cess­ful­ly to ­treat a varie­ty of hemat­o­log­ic malig­nan­cies. These 2 approach­es ­offer dif­fer­ent ­risks and ben­e­fits ­which are dis­cussed in ­this ­review. Timing of trans­plan­ta­tion and selec­tion of ­patients are ­also dis­cussed. New inno­va­tions in ­stem ­cell trans­plan­ta­tion includ­ing umbil­i­cal ­cord ­blood and non-myel­oa­bla­tive trans­plan­ta­tion are ­reviewed.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail